Zhiliang Wang1, Liyun Zhong2, Guanzhang Li1, Ruoyu Huang1, Qiangwei Wang1, Zheng Wang2, Chuanbao Zhang2, Baoshi Chen2, Tao Jiang1,2,3,4, Wei Zhang2. 1. Beijing Neurosurgical Institute, Capital Medical University Beijing, China. 2. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University Beijing, China. 3. China National Clinical Research Center for Neurological Diseases Beijing, China. 4. Center of Brain Tumor, Beijing Institute for Brain Disorders Beijing, China.
Abstract
BACKGROUND: Glioma is the most common and deadliest malignant primary intracranial brain tumor in adults. It remains unclear whether the pre-treatment peripheral blood test parameters might serve as biomarkers for treatment outcome. The purpose of the current study was to investigate the predictive and prognostic value of pre-treatment peripheral blood test parameters in glioma. METHODS: In total, 288 glioma patients with complete results of pre-operation peripheral blood test, clinical information and tumor transcriptome data from Chinese Glioma Genome Atlas (CGGA project) were enrolled in our study. Receiver operating characteristic (ROC) curve, Kaplan-Meier analysis and Cox proportional hazards models were performed to evaluate the diagnostic and prognostic value of pre-treatment peripheral blood test parameters in glioma patients. RESULTS: The white blood cells (WBC) and neutrophils (NEU) counts and neutrophil to lymphocyte ratio (NLR) were positively correlated with tumor grade. IDH mutation and 1p/19q codeletion occurred frequently in patients with higher NEU counts and NLR. We also found that glioma patients with higher NEU or NLR were more likely to have a significantly decreased overall survival. Meanwhile, NEU count was a prognostic marker for TMZ standard treatment GBM patients or IDH wild-type GBM patients. Further biological and functional analysis revealed that NEU count was positively associated with cell cycle and DNA duplication. CONCLUSION: Our study was first to highlight the clinical significance of NEU count in GBM clinical treatment, which should be fully valued for clinical prediction and precise management. AJTR
BACKGROUND:Glioma is the most common and deadliest malignant primary intracranial brain tumor in adults. It remains unclear whether the pre-treatment peripheral blood test parameters might serve as biomarkers for treatment outcome. The purpose of the current study was to investigate the predictive and prognostic value of pre-treatment peripheral blood test parameters in glioma. METHODS: In total, 288 gliomapatients with complete results of pre-operation peripheral blood test, clinical information and tumor transcriptome data from Chinese Glioma Genome Atlas (CGGA project) were enrolled in our study. Receiver operating characteristic (ROC) curve, Kaplan-Meier analysis and Cox proportional hazards models were performed to evaluate the diagnostic and prognostic value of pre-treatment peripheral blood test parameters in gliomapatients. RESULTS: The white blood cells (WBC) and neutrophils (NEU) counts and neutrophil to lymphocyte ratio (NLR) were positively correlated with tumor grade. IDH mutation and 1p/19q codeletion occurred frequently in patients with higher NEU counts and NLR. We also found that gliomapatients with higher NEU or NLR were more likely to have a significantly decreased overall survival. Meanwhile, NEU count was a prognostic marker for TMZ standard treatment GBM patients or IDH wild-type GBM patients. Further biological and functional analysis revealed that NEU count was positively associated with cell cycle and DNA duplication. CONCLUSION: Our study was first to highlight the clinical significance of NEU count in GBM clinical treatment, which should be fully valued for clinical prediction and precise management. AJTR
Authors: Junjie Ma; James Kuzman; Abhijit Ray; Benjamin O Lawson; Brian Khong; Si Xuan; Andrew W Hahn; Hung T Khong Journal: Sci Rep Date: 2018-03-06 Impact factor: 4.379
Authors: Paige M Bracci; Terri Rice; Helen M Hansen; Stephen S Francis; Sean Lee; Lucie S McCoy; Pavan P Shrestha; Gayathri Warrier; Jennifer L Clarke; Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch Journal: J Neurooncol Date: 2022-06-18 Impact factor: 4.506
Authors: Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244